公开(公告)号：US07022322B2

公开(公告)日：2006-04-04

申请号：US10299940

申请日：2002-11-19

申请人： Robert Koll ,  Jutta Müller-Derlich ,  Stephan Felix ,  Petra Reinke ,  Stefan Brehme ,  Gert Baumann ,  Reiner Spaethe

发明人： Robert Koll ,  Jutta Müller-Derlich ,  Stephan Felix ,  Petra Reinke ,  Stefan Brehme ,  Gert Baumann ,  Reiner Spaethe

IPC分类号： A61K39/395

CPC分类号： C07K1/22 ,  A61K35/16 ,  B01D15/3809 ,  C07K16/2869 ,  Y10S424/81

摘要： Immunoapheresis treatment for cardiomyopathy comprises passing the patient's plasma over a column having coupled thereto a specific ligand for human immunoglobulin, thereby removing a significant portion of the immunoglobulin from the patient's plasma, and then reinfusing the plasma to the patient. The invention is the use of a specific ligand for human immunoglobulin in the manufacture of a column having the ligand coupled thereto, the column being useful for immunoapheresis treatment of a patient with cardiomyopathy. The specific ligand binds, and thereby removes, human autoantibodies which are harmful to cardiac tissue such as antibodies against β1-adrenergic receptors, ADP-ATP carriers, α and β myosin heavy chains, and adenine nucleotide translocators. Immunoapheresis treatment using the column results in improvement of hemodynamic parameters such as mean arterial pressure, mean pulmonary pressure, pumonary capillary wedge pressure, right atrial pressure, cardiac output, cariac index, stroke volume index, and systemic vascular resistance.

摘要翻译： 用于心肌病的免疫分离治疗包括将患者的血浆通过与其连接的用于人免疫球蛋白的特异性配体的柱，从而从患者血浆中除去大部分免疫球蛋白，然后将血浆重新输入患者体内。 本发明是用于人免疫球蛋白的特异性配体用于制备具有偶联配体的柱，该柱可用于对患有心肌病的患者的免疫分离治疗。 特异性配体结合并从而除去对心脏组织有害的人自身抗体，例如针对β1 - 肾上腺素能受体，ADP-ATP载体，α和β肌球蛋白重链的抗体和腺嘌呤核苷酸转运蛋白 。 使用柱的免疫分析法治疗可改善血流动力学参数，如平均动脉压，平均肺压，血管毛细血管楔压，右心房压，心输出量，Cariac指数，卒中体积指数和全身血管阻力。